TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Price, Forecast & Analysis
USA - NASDAQ:TRIB - US8964385046 - ADR
TRIB Key Statistics, Chart & Performance
The current stock price of TRIB is 1 USD. In the past month the price decreased by -6.1%. In the past year, price decreased by -87.58%.
TRIB Latest News, Press Relases and Analysis
TRIB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.21 | 218.95B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.58 | 193.16B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.51 | 146.46B | ||
| SYK | STRYKER CORP | 27.53 | 138.63B | ||
| MDT | MEDTRONIC PLC | 16.35 | 115.98B | ||
| IDXX | IDEXX LABORATORIES INC | 57.27 | 57.77B | ||
| BDX | BECTON DICKINSON AND CO | 12.55 | 51.32B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.74 | 49.40B | ||
| RMD | RESMED INC | 24.89 | 35.96B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.19 | 33.92B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 16.88 | 26.98B | ||
| DXCM | DEXCOM INC | 32.89 | 23.99B |
Related stock screener links
About TRIB
Company Profile
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Company Info
TRINITY BIOTECH PLC-SPON ADR
Ida Business Park, Bray, Co Wicklow
DUBLIN WICKLOW IE
CEO: Ronan O'Caoimh
Employees: 380
Phone: 1135312955111
TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ
What does TRINITY BIOTECH PLC-SPON ADR do?
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
What is the current price of TRIB stock?
The current stock price of TRIB is 1 USD. The price increased by 1.96% in the last trading session.
Does TRIB stock pay dividends?
TRIB does not pay a dividend.
How is the ChartMill rating for TRINITY BIOTECH PLC-SPON ADR?
TRIB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Should I buy TRIB stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TRIB.
Can you provide the market cap for TRINITY BIOTECH PLC-SPON ADR?
TRINITY BIOTECH PLC-SPON ADR (TRIB) has a market capitalization of 19.19M USD. This makes TRIB a Nano Cap stock.
What is the Short Interest ratio of TRINITY BIOTECH PLC-SPON ADR (TRIB) stock?
The outstanding short interest for TRINITY BIOTECH PLC-SPON ADR (TRIB) is 14.41% of its float.
TRIB Technical Analysis
TRIB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TRIB. TRIB has a bad profitability rating. Also its financial health evaluation is rather negative.
TRIB Financial Highlights
Over the last trailing twelve months TRIB reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 16.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.78% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRIB Forecast & Estimates
For the next year, analysts expect an EPS growth of 65.8% and a revenue growth 10.13% for TRIB